Shots:

• AbCellera to receive milestones and royalties on products that are derived from its Ab discovery platform. Additionally- AbCellera has the option to invest in pre/ clinical development in exchange for an increased share of product sales
• The collaboration will accelerate the translation of a novel research & cancer drug target into a first-in-class Ab therapeutics for patients with advanced cancers and limited treatment option
• LEFTY1 is a dual inhibitor of the NODAL/SMAD2 and BMP7/SMAD5 pathway that regulates cancer stem cell biology and unregulated tumor cell growth

 to   | Ref: Businesswire | Image: AbCellera